mTOR acts in a synergistic manner to inhibit tumor growth in mouse prostate and lung cancer models, and phosphorylated or activated mTOR is found in 74% of the NSCLCs, making it an additional target for NSCLC therapy (Marinov et al., 2007). This evidence concerns the gene MTOR and neoplasm.